Benzinga··Vandana SinghTempus AI Surges on AACR Data Windfall Despite Jefferies Skepticism
Tempus AI shares jumped 7.3% to $49.34 after 31 cancer research abstracts were accepted for AACR conference, though analyst coverage turns cautious.
TEMcolorectal cancerprecision medicine